capecitabine

Type: Keyphrase
Name: capecitabine
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Forum Post: side effects after big op

> Cancer types> Bowel (colon & rectum) cancer> Bowel (Colon & Rectum) Cancer Group - Discussion Forum> side effects after big opDiscussion toolsKeywordsside effects after big opBowel (colon & rectum) cancerA group for anyone affected by colon, ... [Published Macmillan Cancer Support - Apr 18 2014]
Entities: Rectum, Cancer, capecitabine
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Maintenance Therapy for Colorectal Cancer

Maintenance therapy has become quite a hot topic for those of us working in the field of solid tumor malignancies. Our original concept of chemotherapy for solid tumors was to give a certain number of cycles and then stop treatment, or to continue treatment ... [Published Cancernetwork.com - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

GI Research Improving Quality of Life in Rectal, Colorectal Cancers

Image ToolsImproving quality of life, through more convenient treatment for patients with rectal cancer and by reducing unnecessary treatment for patients with advanced colorectal cancer, was the subject of two studies presented at the Gastrointestinal ... [Published Oncology Times - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Sales of cancer drugs soar once again at Roche

Roche has posted a strong set of financials for the first quarter, again bolstered by its cancer drugs.
Sales reached 11.50 billion francs, a dip of 1% due to the impact of currency, while pharmaceutical revenues also fell 1% to 9.04 billion francs; Roche ... [Published Pharma Times - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Roche may face EU levies following drug safety breaches

Roche faces a potential $740 million fine from the European Commission after its regulator found a series of pharmacovigilance failures.In 2012 the European Medicines Agency began investigating Roche after ‘deficiencies’ in the manufacturer’s pharmacovigilance ... [Published Pharmafocus - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

ONLINE FIRST: 5-FU Overdose May Be Countered by New Antidote Pill

BY ED SUSMANHOLLYWOOD, Fla. -- An oral antidote to life-threatening toxicity from the rare situation of fluorouracil (5-FU) overdose or hypersensitivity appears to be highly successful, researchers reported here at the National Comprehensive Cancer Network ... [Published Oncology Times - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 11 2014 - 1 reports

Forum Post: Starting chemo tomorrow

Hi everyoneI haven't been on the site for over a week as had problems with internet connection - just as I had found you and felt  there are people out there who could support and advise me!  Anyway, problems sorted, internet connection now restored.I ... [Published Macmillan Cancer Support - Apr 10 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Again, Oxaliplatin Is Toxic and No Benefit in Rectal Cancer

VIENNA, Austria — Yet another rectal cancer study has found that the addition of oxaliplatin to capecitabine chemoradiation in locally advanced disease gives no short-term postoperative benefit and increases toxicity.The finding comes from new data from ... [Published American Journal of Public Health - Apr 07 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 2 reports

Resected Pancreatic Cancer Why Wait for the Inevitable

Related Biotechnology, Pharmaceutical and Healthcare NewsDr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy. ... [Published BioPortfolio - Apr 04 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 3 reports

UPDATE 1-FDA allows Curis to resume testing cancer drug

March 31 (Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial.The drugmaker's shares rose as much as 13 percent ... [Published CNBC - Mar 31 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Drugs and Therapies: Researchers at Department of Clinical and Experimental Medicine Report New Data on Capecitabine Therapy

Today's Medical & Research NewsDrugs and Therapies2014 MAR 27 -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Drugs and Therapies have been published. According to news reporting out of Linkoping, Sweden, by ... [Published NewsRX - Mar 27 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

XELODA® (capecitabine) for Metastatic Breast Cancer

This slideshow reviews drug information for XELOADA® (capecitabine) for treatment of metastatic breast cancer.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 9: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 14: ... [Published Chemotherapy Advisor - Mar 24 2014]

Quotes

...According to news originating from Rotterdam, Netherlands, by NewsRx correspondents, research stated, "Patients aged = 80 years were less likely to complete chemotherapy.Prospective data on chemotherapy for elderly patients with metastatic breast cancer (MBC) remain scarce. We compared the efficacy and safety of first-line chemotherapy with pegylated liposomal doxorubicin (PLD) versus capecitabine in MBC patients aged = 65 years in a multicentre, phase III trial."
"We are contraire to the rest of the world in the Netherlands ― we've just rewritten the guidelines, and we still think there's very little evidence to add chemotherapy to the treatment of"
...MD, professor of clinical oncology and health research at Leeds Institute of Cancer & Pathology, United Kingdom, told Medscape Medical News , "although the results are disappointing that the trial has not shown improved early outcomes for the addition of oxaliplatin, it's very important that we wait for the long-term results in terms of cancer endpoints before we form a firm conclusion about the role of oxaliplatin."
...Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. "We are proud to be at the forefront of research and development with respect to this promising new class of investigational anticancer agents and have initiated a broad clinical development programme for palbociclib that includes breast and non-breast cancers.”"

More Content

All (77) | News (73) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Nektar Presents Pipeline Data - Analyst Blog [Published Mr Top Step - Apr 19 2014]
Forum Post: side effects after big op [Published Macmillan Cancer Support - Apr 18 2014]
Maintenance Therapy for Colorectal Cancer [Published Cancernetwork.com - Apr 17 2014]
INCYTE - JAKAFI’s Label Expansion in Ref. Met... [Published PR inside - Apr 17 2014]
INCYTE - JAKAFI’s Label Expansion in Ref. Met... [Published Live-PR.com - Apr 17 2014]
GI Research Improving Quality of Life in Rectal... [Published Oncology Times - Apr 16 2014]
Sales of cancer drugs soar once again at Roche [Published Pharma Times - Apr 16 2014]
Roche may face EU levies following drug safety ... [Published Pharmafocus - Apr 15 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
ONLINE FIRST: 5-FU Overdose May Be Countered by... [Published Oncology Times - Apr 14 2014]
New Findings on Breast Cancer Described by Inve... [Published NewsRX - Apr 11 2014]
Nektar Presents Pipeline Data [Published Zacks.com - Apr 10 2014]
Forum Post: Starting chemo tomorrow [Published Macmillan Cancer Support - Apr 10 2014]
Cerulean Limps into Nasdaq Debut With $7 Per Sh... [Published Xconomy - Apr 10 2014]
Stepping up fight for cancer drug access [Published Wrexham Leader - Apr 09 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
Forum Post: Re: Chemotherapy and eyesight/joint... [Published Macmillan Cancer Support - Apr 07 2014]
Post-Op Chemo No Help in Adequately Pretreated ... [Published American Journal of Public Health - Apr 07 2014]
Trastuzumab emtansine: indication of major adde... [Published EurekAlert! - Apr 07 2014]
Again, Oxaliplatin Is Toxic and No Benefit in R... [Published American Journal of Public Health - Apr 07 2014]
Forum Post: An update from being diasgnosed in ... [Published Macmillan Cancer Support - Apr 07 2014]
Forum Post: Re: HER2 positive breast cancer [Published Macmillan Cancer Support - Apr 07 2014]
Pfizer’s novel CDK 4/6 inhibitor palbociclib pl... [Published PharmaBiz - Apr 07 2014]
Forum Post: Chemotherapy and eyesight [Published Macmillan Cancer Support - Apr 06 2014]
How I Treat Patients with HER2-Positive Metasta... [Published Oncology Times - Apr 06 2014]
Blog Post: Platelets [Published Macmillan Cancer Support - Apr 05 2014]
Forum Post: Re: Oxy and Capcetabine / Side effe... [Published Macmillan Cancer Support - Apr 05 2014]
Resected Pancreatic Cancer Why Wait for the Ine... [Published BioPortfolio - Apr 04 2014]
Resected Pancreatic Cancer: Why Wait for the In... [Published Diabetes Care - Apr 04 2014]
FDA permits Curis to resume testing for experim... [Published Orthopedics Today - Apr 04 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CAPECITABINE Tablet, Film Coated [Teva Pharmace... [Published DailyMed Drug Label Updates for the last seven ... - Mar 07 2014]
Updated Date: Mar 7, 2014 EST ...
Teva Announces Launch of Generic Xeloda® Tablet... [Published Business Wire Health News - Mar 07 2014]
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda® is marketed by Genentech in the United States. ...
Oncothyreon and Array BioPharma Announce Initia... [Published PR Newswire: Health - Feb 03 2014]
SEATTLE AND BOULDER, CO, Feb. 3, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ:ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced theinitiation of a Phase 1b trial of ONT-380 (ARRY-380) in combinationwith Xeloda® (capecitabine) and/or Herceptin® ...
1

Press Releases

sort by: Date | Relevance
Scientific guideline: Draft capecitabine produc... [Published EMA Ongoing public consultations - Nov 15 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.